All In Biotech

Drug Trial Radar · NCT00003782

Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes

A Three-Arm Randomized Trial to Compare Adjuvant Adriamycin and Cyclophosphamide Followed by Taxotere (AC-T); Adriamycin and Taxotere (AT); and Adriamycin, Taxotere, and Cyclophosphamide (ATC) in Breast Cancer Patients With Positive Axillary Lymph Nodes

Last checked: Nov 19, 2026Latest source record: Mar 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 5,351 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,351

Actual

Start

Mar 1999

Primary completion

Dec 2008

Study completion Dec 2012

Sponsor

Lead sponsor
NSABP Foundation IncResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any tumor cells remaining following surgery. It is not yet known which regimen of combination chemotherapy is more effective in treating breast cancer with positive axillary lymph nodes. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of combination chemotherapy in treating women who have undergone surgery for stage I, stage II, or stage IIIA breast cancer with positive axillary lymph nodes.

Conditions

  • Breast Cancer

Interventions

  • cyclophosphamideDrug

    Arm 1: 600 mg/m2 IV every 21 days for 4 cycles; Arm 3: 500 mg/m2 IV every 21 days for 4 cycles

  • docetaxelDrug

    Arm 1: 100 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 75 mg/m2 IV every 21 days for 4 cycles

  • doxorubicinDrug

    Arm 1: 60 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 50 mg/m2 IV every 21 days for 4 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: 8 years
  2. Disease Free SurvivalTime frame: time to event: breast cancer recurrence; second primary cancer; death from any cause as a first event

Locations

157 sites in 2 countries. Site status is shown where the registry gives one.

  • Comprehensive Cancer Institute

    Huntsville, Alabama

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • CCOP - Western Regional, Arizona

    Phoenix, Arizona

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • California Cancer Center

    Fresno, California

  • Sutter Health Western Division Cancer Research Group

    Greenbrae, California

  • Scripps Cancer Center at Scripps Clinic

    La Jolla, California

  • Rebecca and John Moores UCSD Cancer Center

    La Jolla, California

  • Loma Linda University Cancer Institute at Loma Linda University Medical Center

    Loma Linda, California

  • Pacific Shores Medical Group

    Long Beach, California

  • CCOP - Bay Area Tumor Institute

    Oakland, California

  • Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center

    Orange, California

  • Comprehensive Cancer Centers of the Desert

    Palm Springs, California

  • Stanford Cancer Center at Stanford University Medical Center

    Palo Alto, California

  • Sutter Cancer Center

    Sacramento, California

  • Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego

    San Diego, California

  • Catholic Healthcare West - Westbay Region

    San Francisco, California

  • CCOP - Santa Rosa Memorial Hospital

    Santa Rosa, California

  • Kaiser Permanente Medical Center - Vallejo

    Vallejo, California

  • University of Colorado Cancer Center at University of Colorado Health Sciences Center

    Denver, Colorado

  • CCOP - Colorado Cancer Research Program, Incorporated

    Denver, Colorado

  • University of Connecticut Cancer Center at University of Connecticut Health Center

    Farmington, Connecticut

  • Hartford Hospital

    Hartford, Connecticut

  • CCOP - Christiana Care Health Services

    Wilmington, Delaware

  • MBCCOP - Howard University Cancer Center

    Washington D.C., District of Columbia

  • Morton Plant Hospital

    Clearwater, Florida

  • Halifax Medical Center

    Daytona Beach, Florida

  • Baptist Regional Cancer Institute - Jacksonville

    Jacksonville, Florida

  • University of Miami Sylvester Cancer Center

    Miami, Florida

  • CCOP - Mount Sinai Medical Center

    Miami Beach, Florida

  • MD Anderson Cancer Center Orlando

    Orlando, Florida

  • Sarasota Memorial Hospital

    Sarasota, Florida

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • CCOP - Atlanta Regional

    Atlanta, Georgia

  • Medical College of Georgia Comprehensive Cancer Center

    Augusta, Georgia

  • Dwight David Eisenhower Army Medical Center

    Fort Gordon, Georgia

  • Cancer Research Center of Hawaii

    Honolulu, Hawaii

  • North Idaho Cancer Center

    Coeur d'Alene, Idaho

  • John H. Stroger, Jr. Hospital of Cook County

    Chicago, Illinois

  • Rush-Presbyterian-St. Luke's Medical Center

    Chicago, Illinois

Showing 40 of 157 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.